

and long-term effects of deutetrabenazine treatment on weight and metabolic parameters in individuals treated for TD.

Methods. Two 12-week, randomized placebo-controlled trials (RCTs) of deutetrabenazine for patients with TD evaluated either fixed dosing (AIM-TD; 12, 24, or 36 mg) or dose titration (ARM-TD; max dose, 48 mg/day). Patients completing ARM-TD or AIM-TD were included in an open-label extension (OLE) study, in which all patients underwent response-driven titration of deutetrabenazine from 12 mg/day up to a maximum total dose of 48 mg/day. Weight, body mass index (BMI), serum glucose, serum total cholesterol, and serum triglycerides were evaluated at baseline and during treatment in the RCTs and in the OLE.

Results. In the RCTs, 282 and 133 patients received deutetrabenazine or placebo. At baseline, 77% of patients used DRAs. At Week 12, no meaningful changes in weight were observed, with mean (standard error) weight changes of 0.9–1.2 (0.3–0.5) and 0.2 (0.3) kg in the deutetrabenazine and placebo groups, respectively, and mean BMI changes of 0.3–0.5 (0.1–0.2) and 0.1 (0.1) kg/m². 337 patients were included in the analysis of the OLE study. No meaningful changes were observed in weight (mean change: 0.4 [0.4] kg at Week 54, –0.5 [0.6] kg at Week 106, and –1.1 [0.6] kg at Week 145) or BMI (mean change: 0.1 [0.2] kg/m² at Week 54, –0.2 [0.2] kg/m² at Week 106, and –0.3 [0.2] kg/m² at Week 145). Across the studies, no meaningful changes were observed in triglyceride, cholesterol, or glucose levels.

Conclusion. Deutetrabenazine does not affect common metabolic parameters in patients with TD, even during long-term exposure.

Funding. Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel

Weight Gain and Treatment Interruptions with Second-Generation Oral Antipsychotics: Analysis of Patients with Schizophrenia or Bipolar I Disorder

Michael J. Doane, PhD¹, Leona Bessonova, PhD¹, Kathleen Mortimer, ScD, MPH², Harry Cheng, MA, MPH², Gregory Donadio, MA², Thomas Brecht, MS², Amy K. O'Sullivan, PhD¹, Hannah Cummings, PhD¹, David McDonnell, MD³ and Jonathan M. Meyer, MD⁴

¹Alkermes, Inc., Waltham, MA, USA, ²OMI, Inc., Boston, MA, USA, ³Alkermes Pharma Ireland Ltd., Dublin, Ireland, and ⁴University of California, San Diego School of Medicine, Department of Psychiatry, La Jolla, CA, USA

Presenting Author: Michael J. Doane

Abstract

Among patients with schizophrenia (SZ) and bipolar I disorder (BD-I) treated with second-generation antipsychotics (SGAs),

clinically-significant weight gain (CSWG) and treatment interruptions (TIs) are challenges that may result in morbidity/mortality. CSWG and TIs were assessed among patients who initiated oral SGAs of moderate-to-high weight gain risk (no exposure to index SGAs/first-generation antipsychotics for =12 months) using medical records/claims (OMI Data Cloud; January 2013–February 2020). Outcomes included CSWG (=7% increase in baseline weight) and TIs (switches [to SGAs of low weight gain risk/long-acting injectables] or discontinuations [no SGAs for >30 days]). Descriptive analyses included proportions of patients with CSWG and TIs, and median time to these outcomes.

Approximately three-quarters of patients were overweight/obese at baseline (SZ: N=8,174; BD-I: N=9,142). Within 3 months of SGA initiation, 12% of all patients experienced CSWG. For patients on treatment with index SGAs for >6 months (SZ: 29%; BD-I: 27%), 28% (SZ) and 30% (BD-I) experienced CSWG during follow-up. Median time to CSWG was 14 weeks. CSWG results were numerically similar among patients with SZ and BD-I.

Over 96% of patients had TIs during follow-up (median time of 12 [SZ] and 13 [BD-I] weeks). Among patients with CSWG and subsequent TIs and weight measurements, 74% did not return to baseline weight after interrupting treatment; the remainder returned to baseline weight with median times of 38 (SZ) and 39 (BD-I) weeks. Results suggest that most patients with CSWG do not return to baseline weight after stopping treatment with oral SGAs of moderate-to-high weight gain risk.

Funding. Alkermes, Inc.

Othello Syndrome: Delusional Disorder - Jealous Type ≠ Violence

Elizabeth Soyeon Ahn, MD and
Jacqueline A. Hobbs, MD, PhD

University of Florida College of Medicine, Department of Psychiatry, Gainesville, FL, USA

Presenting Author: Elizabeth Soyeon Ahn

Abstract

Background. Othello syndrome, also known as morbid jealousy, pathological jealousy, and conjugal paranoia, is a rare delusional disorder related to partner's infidelity. There are no large scale or comprehensive studies on delusional jealousy, and only few case reports and cases series leave delusional disorder jealous type (DDJT) largely unknown. Herein, we report a case of DDJT, its possible etiology and describe its characteristics, comorbidities, and interventions.

Case Description. A 65-year-old married, retired, and disabled Caucasian male with a history of closed traumatic brain injury and chronic pain presented for outpatient care accompanied by his wife with a chief complaint of paranoid delusions. The patient was a car racer when he sustained over 25% total body surface area burns after his motor vehicle crashed at the speed of almost